President Donald Trump signed an executive order on April 18, 2023, directing the Food and Drug Administration (FDA) to expedite reviews of psychedelic drugs like ibogaine for treating mental health conditions such as post-traumatic stress disorder (PTSD). The move aims to accelerate access to new medical research and treatments based on these substances. According to multiple reports, the executive order instructs the FDA to prioritize the review of psychedelics already designated as breakthrough therapy drugs.
Key Takeaways
President Trump signed an executive order directing the FDA to expedite reviews of psychedelic drugs like ibogaine for treating mental health conditions such as PTSD. The move includes $50 million in federal funding and opens pathways under the Right To Try rule.
- Executive order prioritizes review of breakthrough therapy psychedelics
- $50 million allocated for ibogaine research
- FDA to issue national priority vouchers cutting review times from months to weeks
- Ibogaine clinics report treating thousands despite heart risks
- Veterans and conservative groups champion the drug's potential
⚖
▼Source Claims Check
High ConsensusAll 12 publishers report consistent facts across 3 key claims.
| Claim | Status | Reason | |
|---|---|---|---|
| Executive Order | Broad Agreement | $50 million allocated for research | |
| Ibogaine Trials | Broad Agreement | First-ever human trials of ibogaine in the U.S. | |
| National Priority Vouchers | Broad Agreement | FDA to issue national priority vouchers for three psychedelics |
Executive Order
Broad Agreement$50 million allocated for research
Ibogaine Trials
Broad AgreementFirst-ever human trials of ibogaine in the U.S.
National Priority Vouchers
Broad AgreementFDA to issue national priority vouchers for three psychedelics
This analysis is AI-generated and may not perfectly represent each source's reporting. Always read the original articles for full context.
Trump announced that $50 million will be dedicated to federal research into ibogaine, a drug that veteran groups have said can help treat PTSD. The order also opens a pathway for ibogaine to be administered to 'desperately ill patients' under the FDA's Right To Try rule. Health Secretary Robert F. Kennedy Jr., who has championed the use of drugs like ibogaine, stated that the reforms would pave the way for these substances to be reclassified after successful clinical trials.
During the announcement, podcaster Joe Rogan revealed he had texted Trump about ibogaine as a treatment for depression and PTSD. According to Sky News, Trump responded positively, saying 'Sounds great. Do you want FDA approval? Let's do it.' Veteran Marcus Luttrell also expressed his support, telling Trump that the drug had changed his life for the better.
Ibogaine, derived from a shrub native to Africa, is currently classified as a Schedule I substance by the Drug Enforcement Administration (DEA), grouping it alongside heroin and ecstasy. Despite its legal status, ibogaine has been used in some countries to treat mental health conditions. Studies have shown that ibogaine can cause hallucinations and has been linked to cardiac-related fatalities. However, recent research suggests it may reduce cravings and withdrawal symptoms in patients with substance abuse disorders.
The executive order also includes provisions to improve data sharing between the FDA and the Department of Veterans Affairs, as well as facilitate fast rescheduling of any psychedelic drugs that become FDA approved. This initiative is seen as a significant step toward addressing the mental health needs of veterans and others suffering from severe mental illness.
The FDA will issue national priority vouchers for three psychedelics next week, allowing certain drugs to be approved quickly if they align with national priorities. These vouchers can cut review times from several months to a period of weeks. The agency is also taking steps to clear the way for the first-ever human trials of ibogaine in the U.S.
Trump's action surprised many longtime advocates and researchers in the psychedelic field, given that ibogaine is known to sometimes trigger potentially fatal heart problems. The National Institutes of Health briefly funded research on the drug in the 1990s but discontinued it due to its cardiovascular toxicity.
How this summary was created
This summary synthesizes reporting from 12 independent publishers using AI. All sources are cited and linked below. NewsBalance is a news aggregator and media literacy tool, not a news publisher. AI-generated content may contain errors or inaccuracies — always verify important information with the original sources.